AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05993858 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 3cycles (Toripalimab + cetuximab)
Description: Toripalimab by intravenous (IV) infusion every 3 weeks (Q3W), 3 preoperative and 17 consolidated doses.~The preoperative starting dose of cetuximab is 400 mg/m\^2 by IV infusion over 120 minutes for 1 week, subsequently followed by 250 mg/m\^2 IV infusion over 60 minutes, from week 2 to 9.
Study NCT05993858 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery
Description: After neoadjuvant therapy, patients would accept surgery within 11-13 weeks.
Study NCT05993858 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy or chemoradiotherapy
Description: Adjuvant radiotherapy was given 4 weeks after surgery. Patients with positive intraoperative pathological margins/extra lymph node envelope invasion are treated with an additional cisplatin synchronous chemotherapy.
Study NCT04805034 — intervention group
Intervention type: OTHER
Intervention: Age, BMI,Baseline HBV DNA, Baseline HBeAg level, Baseline HBsAg level, Antiviral treatment, Serum ALT level
Description: Exposure factors: Age, BMI, Family history, Baseline HBV DNA, Baseline HBeAg level, Baseline HBsAg level, Antiviral treatment, Serum ALT level
Study NCT04841512 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: XT-150
Description: non-viral Plasmid DNA encoding an IL-10 variant transgene
Study NCT04841512 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XT-150
Description: non-viral Plasmid DNA encoding an IL-10 variant transgene
Study NCT05029414 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular Therapy
Description: Endovascular treatment of stroke is the non-surgical treatment for the sudden loss of brain function due to blood clots. The blood clot is removed from the blood via devices (i.e. stent-retriever, aspiration catheters and balloon guide) to achieve revascularization.
Study NCT06035991 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heart transplantation
Description: Heart transplantation in patients who have obtained a favourable and motivated opinion from the Multidisciplinary Consultation Meeting (RCP) of the cardiac surgery department of the Hospital Pitié-Salpêtrière
Study NCT05231486 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance
Description: CO-OP uses cognitive problem solving techniques to facilitate motor skill acquisition. The therapist facilitates with guided discovery the child to generate solution for problems in their performance areas.
Study NCT04509960 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: direct laryngoskopy
Description: Proseal Laryngeal mask inserted with direct laryngoskopy
Study NCT05106504 — intervention group
Intervention type: DRUG
Intervention: Medical Cannabis
Description: Patients will be assessed before and after use of Medical cannabis via inhaled dried buds or sublingual oil extract
Study NCT05274802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-4
Description: Single dose of ALS-4 before Breakfast
Study NCT05274802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of placebo before Breakfast
Study NCT05274802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-4
Description: Dose three separate times in crossover fashion: (1) fasted morning dose; (2) fed morning dose; (3) fasted evening dose
Study NCT05274802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-4
Description: Multiple dose of ALS-4 up to two times daily
Study NCT05274802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Multiple dose of placebo up to two times daily
Study NCT05532449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous dizocine
Description: Intravenous dizocine (0.03mg/kg diluted to 5 ml)
Study NCT05426642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-health Video KaSEH
Description: The e-health video KaSEH is produce based on Protection Motivation Theory to enhance women's motivation towards cervical cancer screening.
Study NCT05426642 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Brochure
Description: The brochure contain the information regarding cervical cancer and its screening
Study NCT05426642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brochure
Description: The brochure contain the information regarding cervical cancer and its screening
Study NCT05944042 — intervention group
Intervention type: OTHER
Intervention: Observational Transplant Analysis
Description: Identify more accurate predictive models of transplant risk
Study NCT05712135 — intervention group
Intervention type: OTHER
Intervention: supine position
Description: The patient group whose cuff pressure was measured in the supine position
Study NCT05712135 — intervention group
Intervention type: OTHER
Intervention: prone position
Description: The patient group whose cuff pressure was measured in the prone position
Study NCT05712135 — intervention group
Intervention type: OTHER
Intervention: semi-fowler position
Description: The patient group whose cuff pressure was measured in the semi-fowler position
Study NCT06494787 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Aliya Pulse Electric Field sysem and pembrolizumab
Description: This is a phase 2 study to determine the efficacy of the Aliya Pulse Electric Field system and pembrolizumab in prolonging progression free and overall survival of patients with advanced soft tissue sarcoma
Study NCT04919252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: * Crohn's disease (CD): If a subject does not respond to vedolizumab 300mg iv 0, 2, and 6 weeks for induction, an additional dose of vedolizumab 300 mg will be given at week 10. On the other hand, Maintenance therapy should be continued every 8 weeks from week 14 in responding patients, and for some patients who have experienced a decrease in their response, it can be given every 4 weeks. The maximum dosing period is 54 weeks.~* Ulcerative colitis (UC): If a subject responds to vedolizumab 300mg iv 0, 2, and 6 weeks for induction, maintenance therapy should be continued every 8 weeks from week 14, and for some patients who have experienced a decrease in their response, it can be given every 4 weeks. The maximum dosing period is 54 weeks.
Study NCT04910477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: ultrasonic nebulization of dexmedetomidine (1 mg/kg diluted in 4 mL saline) twice daily for three days.
Study NCT04910477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine/atropine
Description: nebulization of 20 µ/kg neostigmine and 10 µ/kg atropine mixed in 4 ml) twice daily for three days.
Study NCT04910477 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: nebulization of saline placebo in 4 ml) twice daily for three days.
Study NCT05217693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BB-1705
Description: BB-1705 is an ADC consisting of an engineered humanized IgG1κ monoclonal antibody conjugated to the cytotoxic agent eribulin via a cathepsin-cleavable valine-citrulline linker. BB-1705 has a molecular weight of approximately 152 kDa, including two molecules of eribulin via the linker.
Study NCT04645771 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires to assess the quality of life (EQ-5D, CVVQ, CIVIQ, AVVQ, Patient satisfaction survey)
Study NCT04998487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3471851
Description: Administered SC.
Study NCT05356468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured pain neuroscience education
Description: Structured pain neuroscience~* Neurophysiology of pain~* The PNE occurred with the use of pictures, examples, metaphors and drawings as needed~* Metaphor Alarm system: Your nerves working like an alarm system to protect you.~* BOOKLET Consist of education about pain neurophysiology.(31)~* Steps of booklet :~  1. Extract content~ 2. English to Urdu translation~ 3. Content Validity~ 4. Expert Panel review by Physiotherapists~ 5. Content validity Analysis review(Focus Group)~ 6. Pilot study 4 to 5 patients~ 7. Content improved (PNE) and Finalized~ 8. After Analysis RCT
Study NCT05356468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: ELECTROTHERAPY MODALTIES-15 min~* IFC (interferential current)IFC will be administered using following parameters: 80-150 watts, 4000 Hz, sweep on, 16.0-17.0 CV(26)~* Hot pack(27)~Therapeutic exercises~* Strengthening (Back extensors, quadriceps, hamstring and VMO, gluteus maximums, gluteus medius, transverse abdominis.~* Stretching hamstring and, calf stretching. Soft tissue mobilization(5) McKenzie based exercises(28) BALANCE EXERCISES~* Single Leg Stance (static balance) Patient is instructed to stand on one leg,close his/her eyes and maintain this position as long as they could.~* Tandem gait (dynamic balance) patient is instructed to walk a total of 5 laps on a 2-meter-long line with the heel of the front foot touching the fingertip of the back foot.(29)~POSTURAL TRAINING~* good posture when sitting standing and while driving~* Avoid weight lifting~* Avoid too much bed rest~* Sit in firm places. (30)
Study NCT06374914 — intervention group
Intervention type: DRUG
Intervention: Intravesical Solution
Description: Alkalinization of urine 1 day before the procedure Emptying the bladder with a catheter before the procedure mixing 1000 mg gemcitabine in 50 ml saline 90 minutes after administration 37.5 mg docetaxel mixed 120 minutes after administration in 50 ml saline maintanence if there is a 6 week induction response
Study NCT06375434 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT04981821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GO-EXCAP Mobile App
Description: A mobile app delivery platform to deliver an exercise program \[Exercise for Cancer Patients (EXCAP©®)\]. EXCAP©®) is a progressive walking and resistance exercise program
Study NCT04981821 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Placebo Control
Description: Participants will meet with an oncology nurse (for approximately 60 min) to review the NCI booklet Chemotherapy and You: Support for People With Cancer, which includes facts about chemotherapy and its side effects. They will be provided with NCI online resources to review at home.
Study NCT04801134 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: as per previous description
Study NCT01852682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21
Study NCT05773950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosaprepitant
Description: The subject is then moved to the operating room and undergoes induction of general anesthesia. After the induction of anesthesia, 5 mg of dexamethasone and 0.075 mg of palonosetron are intravenously administered.~In the experimental group, the subject is then moved to the operating room and undergoes induction of general anesthesia. After the induction of anesthesia, 5 mg of dexamethasone and 0.075 mg of palonosetron are intravenously administered.
Study NCT05773950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: On the day of surgery, in the preoperative holding area, the principal investigator administers the study drug to the participants. During the study drug administration period, the principal investigator observes the presence of specific symptoms and abnormalities at the injection site of participants.~In the case of the control group, the study drug is 150 ml of normal saline, which is visually indistinguishable from the dilute solution of the fosaprepitant, administered over 30 minutes.
Study NCT05314764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Description: Patients will receive intravenous cefiderocol every 6 to 8 hours for 4 to 6 doses.
Study NCT04779190 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Description: Gallium-aluminum-arsenide diode laser device
Study NCT04779190 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound
Description: Therapeutic pulsed ultrasound with a frequency of 1 MHz
Study NCT04779190 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based exercise
Description: Home-based exercises 3 days a week; each exercise comprises one set with 5 repetitions over 4 weeks.
Study NCT04779190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based exercise
Description: Home-based exercises 3 days a week; each exercise comprises one set with 5 repetitions over 4 weeks.
Study NCT05802394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Later-line therapy
Description: Another chemotherapy regimen, targeted therapy, or immunotherapy
Study NCT06239298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZG005 Powder for Injection
Description: intravenous infusion(IV), once every 3 weeks
Study NCT06239298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib Tosilate Tablets
Description: The dose groups of Donafenib for dose-exploration stage are set as 0.2g BID, 0.1g BID, and 0.1g QD, oral administration.The dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage
Study NCT04964570 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video _ behavioral change module
Description: A short video (primary outcome) that aimed at reducing stigma towards treatments and increasing help seeking intentions.~The behavioral change module (secondary outcome) is aimed at changing behaviors of sleep, exercise and social support.
Study NCT04669288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: oral azithromycin (12 mg/kg per day for 5 days)~Local investigational drug pharmacies will be provided with active study medication (azithromycin) from a central pharmacy. Azithromycin will be reconstituted with water at the local pharmacy, and will resemble placebo with regards to appearance, flavor, consistency and packaging.
Study NCT04669288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo (12 mg/kg per day for 5 days)~Local investigational drug pharmacies will be provided with placebo from a central pharmacy. Placebo will be reconstituted with water at the local pharmacy, and will resemble azithromycin with regards to appearance, flavor, consistency and packaging.
Study NCT06155604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin 10mg daily
Study NCT06155604 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard maintenance therapy
Description: Prednisolone 5-7.5 mg daily alone or in combination with Mycophenolate mofetil (\<=1.5 g/D) or Azathioprine (\<=150 mg/D)
Study NCT06155604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard maintenance therapy
Description: Prednisolone 5-7.5 mg daily alone or in combination with Mycophenolate mofetil (\<=1.5 g/D) or Azathioprine (\<=150 mg/D)
Study NCT05090995 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Self-Management and Feedback
Description: Self-management brief health intervention that involves passive daily health monitoring using a PPG sensor, active self-monitoring of health and behavior using daily diaries, and the provision of personalized health feedback and advice.
Study NCT05090995 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral Self-Management
Description: Self-management brief health intervention that involves passive daily health monitoring using a PPG sensor, and active self-monitoring of health and behavior using daily diaries.
Study NCT05204329 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MSC Secretome Eye Drops
Description: MSC Secretome eye drop will be dispensed.
Study NCT04817384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graston technique
Description: For Graston practice, children will be asked to sit with a support forward. Vaseline will be used as an intermediate during the application. Instruments made of stainless steel material of a type suitable for the body structures and sizes of the children will be preferred. Larger instruments will be used for larger areas and smaller for smaller regions and fibrocytic areas. The frequency of the plastering and friction movements will be applied in 60 repetitions per minute. While the graston technique is applied to individuals; Superficial muscles in the entire dorsal region will be included in the treatment. These muscles, respectively, the levator scapula, trapezius, and erroctor spina muscles were selected. The treatment time takes approximately 20-25 minutes depending on the area being treated. The instant effects of the people will be looked at.
Study NCT04817384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical Massage
Description: In the neck massage application, the patient should be prepared, and the clothes in the upper back and neck area should be removed. The position of the patient will be in a sitting position with a pillow in front of him. The trapezius, erector spina and levator scapula muscles will be applied with one hand or both hands, starting with general stroking. The intermediate to be used is baby oil or natural oils. The application time will be approximately 20 minutes.
Study NCT05539833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSH01 injection
Description: TCR-T cell injection
Study NCT04818424 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft exosuit
Description: A soft exosuit is a textile-based wearable robot that is worn on the paretic ankle. Soft exosuits provide assistive torques through retraction of Bowden cables that connect distally to anchor points on front and back of the ankle, assisting with dorsiflexion during swing for foot clearance, and plantarflexion during late stance to assist with propulsion, respectively. Exosuit assistance is provided synchronously based on the wearer's gait, as detected by integrated inertial measurement units.
Study NCT04818424 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gait training without exosuits
Description: Control intervention will implement gait training without exosuits. Other elements of intervention are similarly structured as with REAL, with the only exception of using exosuits.
Study NCT05031988 — intervention group
Intervention type: OTHER
Intervention: No intervention will be used.
Description: Determinants of physical activity and mental health among the students during Covid-19 lockdown will be assessed.
Study NCT04806139 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote Enhance Fitness
Description: The Remote Enhance Fitness Intervention will include live-streamed exercise classes (1-hour long, 3 days per week, 16 weeks). Certified Enhanced Fitness trainers will lead the exercise classes per Enhance Fitness guidelines, including modifications and gradual progression. During weeks 8-12 participants will have the option to wear a Fitbit during classes for up to 6 class session (2 weeks) for collection of heart rate, steps, and physical activity intensity along with ratings of perceived exertion (RPE) during exercise classes.
Study NCT06593249 — intervention group
Intervention type: OTHER
Intervention: No Intervention: Observational Cohort
Description: no intervention, observational study
Study NCT06613100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xaluritamig
Description: Intravenous (IV) infusion
Study NCT05672472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sivelestat sodium
Description: Continuous infusion of sivelestat sodium for 5 days
Study NCT05672472 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sivelestat sodium
Description: Continuous infusion of sivelestat sodium for 5 days
Study NCT06095505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib enteric-coated tablets
Study NCT06718452 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PEA-LUT 1 sachet
Description: 1 dose day to be absorbed sublingually
Study NCT06718452 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PEA-LUT 2 sachet day
Description: 1 sachet two times a day to be sublingually absorbed
Study NCT06718452 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same administration of PEA-LUT
Study NCT06725121 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Atezolizumab & Bevacizumab
Description: Atezolizumab \& Bevacizumab will be initiated as part of the study, as per standard treatment protocol. Administration of Atezolizumab and Bevacizumab will be performed according to SOC in approx. 21-days intervals. Clinical follow up during treatment will be done as per SOC in medical and surgical oncology clinics at UHN.
Study NCT06725121 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Yttrium-90 (Y-90)
Description: Storage, administration and treatment of Y90-RE will be done according to established treatment protocols and standard of care at UHN.
Study NCT06725121 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic body radiotherapy (SBRT)
Description: Dose and administration frequency of SBRT will be done as per current standards for treating HCC at UHN.
Study NCT06734273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mounjaro
Description: In this study, the intervention group (n=21) are patients who will undergo sleeve gastrectomy and receive tirzepatide after surgery. Patients who were selected in this arm will undergo a 4-week dose escalation period. Starting at 6 months they will receive weekly 2.5mg doses (for 4 weeks). Afterwards, they will receive weekly 5mg doses. They will maintain this dose until 12 months after surgery.